Table I.

Visit schedule in the Drug-Induced Liver Injury Network (DILIN) prospective study

Item	Data source	Baseline visit	6-mo study visit	12- and 24-mo study visit
Eligible patients		Standard DILIa, liver DILIb, control	Standard DILI, liver DILI	Chronic DILIc
Demographics	Interview	✓
Pharmacy use	Interview	✓
Medication compliance	Interview	✓
Family history	Interview	✓
Diagnostic laboratory testsd	Records/visit	✓
Suspect medication use	Interview/records	✓
HCV/HBV laboratory testse	Records/visit	✓	✓
Concomitant medication and CAM use history	Interview/records	✓	✓	✓
Alcohol and smoking	Interview	✓	✓	✓
Physical examination	Visit	✓	✓	✓
Symptom score	Interview	✓	✓	✓
Quality-of-life survey	Interview	✓	✓	✓
Medical history	Interview/records	✓	✓	✓
Standard laboratory tests	Records/visit	✓	✓	✓
Research blood sample	Visit	✓	✓	✓
Research urine sample	Visit	✓	✓	✓
Liver imaginga	Records	✓	✓	✓

^aStandard DILI case = normal liver biochemistries or no known liver disease before starting the suspect medication.

^bLiver DILI case = known chronic liver disease such as chronic HCV or HBV or fatty liver before starting the suspect medication.

^cChronic DILI case = evidence of persistent laboratory, radiological or pathological abnormalities 6mo after DILI onset.

^dNot done in control patients.

^eOnly in HCV/HBV liver DILI patients.

CAM=complementary and alternative medicine; DILI=drug-induced liver injury; HBV=hepatitis B virus; HCV=hepatitis C virus.